<DOC>
	<DOCNO>NCT00195624</DOCNO>
	<brief_summary>This study evaluate safety usefulness new immunosuppressive drug , alemtuzumab ( Campath ) , patient severe aplastic anemia ( SAA ) . SAA rare serious blood disorder bone marrow stop make red blood cell , white blood cell platelet . Alemtuzumab monoclonal antibody attache kill white blood cell call lymphocyte . In certain type aplastic anemia , lymphocytes responsible destruction stem cell bone marrow , lead decrease blood count . Because alemtuzumab destroys lymphocyte , may effective treat aplastic anemia . Alemtuzumab currently approve treat chronic lymphocytic leukemia also helpful condition require immunosuppression , rheumatoid arthritis immune cytopenia . Patients 2 year age old severe aplastic anemia whose disease respond immunosuppressive therapy recur follow immunosuppressive therapy may eligible study . Participants undergo follow test procedure : - Pretreatment evaluation : Patients medical history , physical examination , blood test , electrocardiogram ( EKG ) , echocardiogram , 24-hour Holter monitor ( continuous 24-hour monitoring electrical activity heart ) , bone marrow biopsy ( withdrawal needle small sample bone marrow analysis ) . - Placement central line , need : An intravenous line ( tube ) place major vein patient 's chest . It stay body entire treatment period use give chemotherapy medication , include antibiotic blood transfusion , need , withdraw blood sample . - Alemtuzumab therapy : Patients admit NIH Clinical Center first injection close monitor side effect . After receive initial small test dose , patient begin first ten daily injection skin , last 2 hour . Once patient tolerate infusion minimal side effect , may give remain infusion outpatient basis . Patients relapse initial response alemtuzumab give cyclosporine see drug boost immune response . - Patients receive transfusion , growth factor , antibiotic therapy , need . - Infection therapy : Patients give aerosolized pentamidine protect lung infection valacyclovir protect herpes infection . - A blood test do vital sign measure every day patient receive alemtuzumab . - Patients echocardiogram 24-hour Holter monitor last dose alemtuzumab . - Blood test do weekly first 3 month alemtuzumab administration , every week 6 month . Patients return NIH follow-up visit 1 month , 3 month , 6 month , yearly 5 year last dose alemtuzumab follow test evaluation : - Blood test - Repeat echocardiogram 3-month visit - Repeat bone marrow biopsy 6 month 12 month alemtuzumab , clinically indicate 5 year .</brief_summary>
	<brief_title>Alemtuzumab Treat Severe Aplastic Anemia</brief_title>
	<detailed_description>Hematopoietic stem cell destruction many human bone marrow failure syndromes recognize secondary immune mechanism . Severe aplastic anemia ( SAA ) life-threatening blood disease effectively treat immunosuppressive drug regimen . However , significant minority patient SAA fail respond single course horse antithymocyte globulin cyclosporine , patient experience relapse , especially discontinuation therapy . Pancytopenia secondary refractory relapse aplastic anemia poor prognosis , death usually result infectious complication . Alemtuzumab ( Campath ) humanize IgG1 monoclonal antibody direct CD52 protein ; CD52 express lymphocyte monocyte . Alemtuzumab ( Campath ) produce profound persistent lymphopenia . The antibody use treat wide range autoimmune disease , lymphoid malignancy , solid organ hematopoietic stem cell transplantation . In limited experience alemtuzumab treatment SAA refractory horse antithymocyte globulin , meaningful hematologic response observe toxicity modest . We therefore propose non-randomized pilot phase II study humanize monoclonal antibody SAA relapse refractory ATG . Commercially available alemtuzumab ( Campath ) administer 10 mg per day subcutaneously 10 day total . The primary end point study response rate 6 month , define longer satisfy blood count criterion SAA . Relapse , robustness hematopoietic recovery 3 6 month , 3 month response , survival , clonal evolution myelodysplasia acute leukemia secondary end point .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA : Relapsed severe aplastic anemia initial hematologic response prior course hATG rATG base immunosuppression Or Refractory severe aplastic anemia respond horseATG rabbit ATGbased immunosuppression The criterion severe aplastic anemia two three criterion : Absolute neutrophil count less equal 500 /mm ( 3 ) Platelets less equal 20,000/mm ( 3 ) Absolute reticulocyte count le 60,000 /microL Age great equal 2 year old great 12 kg Prospective subject parent ( ) /responsible guardian ( ) must able comprehend willing sign inform consent . EXCLUSION CRITERIA : Known Diagnosis Fanconi 's anemia Evidence clonal disorder cytogenetics . In refractory disease setting , prospective subject super severe neutropenia ( ANC less 200 /microL ) exclude result cytogenetics available pending . Infection adequately respond appropriate therapy HIV positivity Failure discontinue herbal supplement Echinacea purpurea Usnea barbata ( Old Man 's Beard ) within 2 week enrollment Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient 's ability tolerate protocol therapy , death within 710 day likely Previous hypersensitivity alemtuzumab component Potential subject cancer active chemotherapeutic treatment take drug hematological effect eligible Current pregnancy , unwilling take oral contraceptive refrain pregnancy childbearing potential Not able understand investigational nature study give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 15, 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Alemtuzumab/Campath</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>T-cells</keyword>
	<keyword>Hematopoiesis</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>SAA</keyword>
</DOC>